Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Legembre

Showing results (61-70 of 87) with videos related to

Pageof 9
Sort By:
Nature Communications|July 2, 2025
Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapyBrice E N Wamba, Tanmoy Mondal, Francis Freenor V, et al.
Cell Death & Disease|October 23, 2022
MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathwaysShoji F Kenji, Keerthi Kurma, Brigitte Collet, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 31, 2021
Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunityZhongshun Liu, Congwei Jiang, Zhangmengxue Lei, et al.
Journal of Medicinal Chemistry|October 12, 2019
Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer CellsAmélie Fouqué, Olivier Delalande, Mickael Jean, et al.
Journal of Medicinal Chemistry|August 4, 2015
A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer CellsAmélie Fouqué, Olivier Delalande, Mickael Jean, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 15, 2025
Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disordersAntoine Tichadou, Eden Lebrault, Assia Samri, et al.
Journal of Gynecology Obstetrics and Human Reproduction|January 9, 2021
Single bilateral ovarian venous return in uterine transplant: Validation in an orthotopic auto-transplant model in the Yucatan minipigLudivine Dion, Maela Le Lous, Krystel Nyangoh Timoh, et al.
The Journal of Clinical Investigation|February 29, 2024
Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance modelsEkjot Kaur, Ritu Agrawal, Rimpy Arun, et al.
Molecular Cancer Research : MCR|April 12, 2008
Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathwayMarie Bénéteau, Mathieu Pizon, Benjamin Chaigne-Delalande, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2011
CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formationNadine Khadra, Laurence Bresson-Bepoldin, Aubin Penna, et al.
Pageof 9

Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Nature Communications|July 2, 2025
Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapyBrice E N Wamba, Tanmoy Mondal, Francis Freenor V, et al.
Cell Death & Disease|October 23, 2022
MMP7 cleavage of amino-terminal CD95 death receptor switches signaling toward non-apoptotic pathwaysShoji F Kenji, Keerthi Kurma, Brigitte Collet, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 31, 2021
Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunityZhongshun Liu, Congwei Jiang, Zhangmengxue Lei, et al.
Journal of Medicinal Chemistry|October 12, 2019
Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer CellsAmélie Fouqué, Olivier Delalande, Mickael Jean, et al.
Journal of Medicinal Chemistry|August 4, 2015
A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer CellsAmélie Fouqué, Olivier Delalande, Mickael Jean, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 15, 2025
Soluble CD95L is a prognostic marker in central nervous system posttransplant lymphoproliferative disordersAntoine Tichadou, Eden Lebrault, Assia Samri, et al.
Journal of Gynecology Obstetrics and Human Reproduction|January 9, 2021
Single bilateral ovarian venous return in uterine transplant: Validation in an orthotopic auto-transplant model in the Yucatan minipigLudivine Dion, Maela Le Lous, Krystel Nyangoh Timoh, et al.
The Journal of Clinical Investigation|February 29, 2024
Small molecules that disrupt RAD54-BLM interaction hamper tumor proliferation in colon cancer chemoresistance modelsEkjot Kaur, Ritu Agrawal, Rimpy Arun, et al.
Molecular Cancer Research : MCR|April 12, 2008
Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathwayMarie Bénéteau, Mathieu Pizon, Benjamin Chaigne-Delalande, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 9, 2011
CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formationNadine Khadra, Laurence Bresson-Bepoldin, Aubin Penna, et al.
Pageof 9